Has Tracy Morgan confirmed using Ozempic?

Yes. Tracy Morgan made public statements in 2024 confirming he uses Ozempic for type 2 diabetes management. He described weight loss as a secondary benefit of treatment. This is a confirmed, on-the-record disclosure, not tabloid speculation.

How is Tracy Morgan's GLP-1 use different from other celebrities?

Morgan confirmed use for type 2 diabetes, the original FDA-approved indication for Ozempic. Most other confirmed celebrity GLP-1 disclosures (Oprah Winfrey, Sharon Osbourne) reference weight management as the primary goal. Many other celebrity associations remain publicly speculated but unconfirmed.

Does Ozempic treat diabetes and cause weight loss at the same time?

Yes. Semaglutide (Ozempic) was approved for T2D in 2017. It lowers blood sugar through multiple mechanisms and also reduces appetite via hypothalamic signaling, producing weight loss of roughly 4 to 6 kg in diabetes patients. The higher-dose formulation (Wegovy) is specifically approved for chronic weight management.

What are the most common side effects of Ozempic?

Nausea affects 15 to 20% of patients and is the most frequently reported side effect, though it usually diminishes over the first weeks of treatment. Other common GI effects include vomiting, diarrhea, and constipation. Rare but serious risks include pancreatitis and gallbladder disease. Ozempic carries a boxed warning about medullary thyroid carcinoma based on animal data.

Did celebrity Ozempic demand cause shortages for diabetes patients?

The FDA reported intermittent shortages of certain Ozempic presentations during 2023 and 2024, coinciding with surging demand partly driven by off-label weight-loss prescribing and celebrity publicity. Patients with type 2 diabetes who relied on semaglutide for glycemic control were directly affected by these supply disruptions.

Tracy Morgan Compared to Other Public GLP-1 Figures

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for Tracy Morgan Compared to Other Public GLP-1 Figures Image: HealthRX.com clinical image

Tracy Morgan's Public GLP-1 Record

In 2024, Tracy Morgan spoke publicly about using Ozempic (semaglutide) to manage his type 2 diabetes. He described concurrent weight loss as a secondary benefit of treatment. This disclosure was direct and unambiguous: Morgan named the drug, identified his diagnosis, and discussed his experience openly.

That directness sets Morgan apart. Most celebrity associations with GLP-1 medications exist in a gray zone of tabloid speculation, unnamed "sources," and physical transformation timelines that invite public guessing. Morgan bypassed all of that.

His history with type 2 diabetes predates the GLP-1 conversation entirely. Morgan has discussed his diabetes diagnosis in interviews going back years, and a 2023 FDA safety communication reinforced the clinical framing around semaglutide's primary approved use for glycemic control in T2D patients.

The Celebrity GLP-1 Disclosure Spectrum

To understand where Morgan sits, consider the full range of public GLP-1 associations as of mid-2026.

At a glance

Confirmed, on-label (T2D): Tracy Morgan (Ozempic, 2024). Named the drug and the diagnosis publicly.
Confirmed, weight management: Oprah Winfrey confirmed GLP-1 use in late 2023 for weight management, later specifying she used a medication in this class. Sharon Osbourne confirmed Ozempic use and discussed significant weight loss publicly.
Confirmed but vague: Charles Barkley confirmed trying a GLP-1 medication in 2024, referencing weight loss goals without specifying a particular drug or diagnosis.
Publicly speculated, not confirmed: Figures like Elon Musk (who referenced Wegovy/Ozempic on social media in 2022 without a clear ongoing confirmation) and numerous others whose names circulate in tabloid GLP-1 lists without direct public statements.

The pattern that emerges: confirmed disclosures cluster around two poles. Weight management dominates the conversation. Morgan's confirmed use for type 2 diabetes is the exception, not the norm, in celebrity GLP-1 media coverage.

Why the Indication Matters Clinically

Semaglutide was first approved by the FDA for type 2 diabetes under the brand name Ozempic in 2017, at doses of 0.5 mg, 1 mg, and later 2 mg weekly. The weight management formulation (Wegovy) arrived in 2021 at a higher dose ceiling of 2.4 mg weekly. Same molecule, different approved uses, different dose ranges.

For patients with T2D, semaglutide's primary job is glycemic control. A 2017 SUSTAIN-6 trial published in the New England Journal of Medicine demonstrated that semaglutide reduced HbA1c by 1.4 to 1.8 percentage points versus placebo, while also showing a 26% reduction in major adverse cardiovascular events. Weight loss in T2D patients on Ozempic typically ranges from 4 to 6 kg (roughly 9 to 13 lbs), meaningful but generally less dramatic than the 12 to 17% body weight reductions seen in obesity trials with higher-dose Wegovy.

This distinction gets lost in celebrity coverage. When the public conversation collapses "Ozempic for diabetes" and "Wegovy for weight loss" into a single narrative, it obscures the clinical reality that GLP-1 receptor agonists serve dual but distinct therapeutic roles.

Morgan's disclosure, by naming both the drug and the diagnosis, reinforces a fact that the hype cycle tends to bury: millions of Americans use these medications because they have a chronic metabolic disease, not because they want to fit into a smaller suit.

How GLP-1 Receptor Agonists Work in Type 2 Diabetes

GLP-1 (glucagon-like peptide-1) is an incretin hormone released by the gut after eating. It triggers insulin secretion from pancreatic beta cells in a glucose-dependent manner, meaning it ramps up insulin when blood sugar is high and backs off when it is not. This built-in safety mechanism gives GLP-1 receptor agonists a lower hypoglycemia risk compared to sulfonylureas or exogenous insulin.

Beyond insulin secretion, GLP-1 receptor agonists suppress glucagon release from alpha cells, slow gastric emptying (which blunts postprandial glucose spikes), and act on hypothalamic appetite centers to reduce food intake. That last mechanism is what produces the weight loss, a welcome secondary effect for the roughly 89% of U.S. adults with T2D who also have overweight or obesity.

A 2021 meta-analysis in The Lancet Diabetes & Endocrinology confirmed that GLP-1 receptor agonists reduce all-cause mortality and major cardiovascular events in T2D patients, cementing their place as first- or second-line therapy in current guidelines from the American Diabetes Association.

Common side effects include nausea (reported in 15 to 20% of patients, typically transient), vomiting, diarrhea, and constipation. More serious but rare risks include pancreatitis, gallbladder disease, and a boxed warning for medullary thyroid carcinoma based on rodent studies, though human risk remains unconfirmed.

What Celebrity Disclosures Teach the Field

The HealthRX.com Medical Team sees three patterns in the celebrity GLP-1 disclosure data that carry real clinical implications.

First, weight-loss framing dominates even when the indication is diabetes. Media coverage of Morgan's Ozempic use frequently led with weight loss in headlines, even though he identified diabetes management as his reason for treatment. This mirrors a broader trend: a 2023 analysis in JAMA Internal Medicine found that social media discussions of semaglutide overwhelmingly focused on cosmetic weight loss, potentially stigmatizing patients who use the same drug for metabolic disease.

Second, confirmed disclosures are still rare relative to speculation. For every Tracy Morgan or Oprah Winfrey who names a drug on the record, dozens of public figures get swept into GLP-1 rumors based on paparazzi photos. The HealthRX.com Medical Team notes this creates a distorted public picture: the loudest signal comes from unverified associations, not from patients describing real therapeutic experiences.

Third, the "celebrity shortage" narrative has real consequences for T2D patients. When GLP-1 medications became culturally associated with celebrity weight loss in 2023 and 2024, supply shortages reported by the FDA affected patients with type 2 diabetes who depended on these drugs for glycemic control. Morgan's story, where GLP-1 use is grounded in a chronic disease diagnosis, serves as a counterweight to the cosmetic framing that contributed to demand surges.

The HealthRX.com Medical Team Take

Tracy Morgan's public Ozempic record is clinically significant precisely because it is ordinary. He is a patient with type 2 diabetes using an FDA-approved medication for that condition, and experiencing weight loss as a predictable pharmacologic effect. That this qualifies as noteworthy says more about the state of public GLP-1 discourse than about Morgan himself.

The HealthRX.com Medical Team recommends that patients and clinicians view celebrity GLP-1 disclosures through three filters: (1) Is the use confirmed or speculated? (2) What is the stated indication? (3) What dose and formulation are referenced? These three data points separate signal from noise.

For patients with T2D considering GLP-1 therapy, Morgan's experience aligns with the clinical evidence: semaglutide provides strong glycemic control with the added benefit of weight reduction, a combination that addresses two of the most common comorbid challenges in type 2 diabetes management.

The celebrity conversation will keep moving. The clinical evidence is what stays.

Frequently asked questions

›

References

Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. https://www.nejm.org/doi/full/10.1056/NEJMoa1607141
Sattar N, et al. GLP-1 receptor agonists and cardiovascular outcomes in type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2021;9(10):653-662. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(21)00203-5/fulltext
FDA Drug Safety Communication: Semaglutide medications marketed for type 2 diabetes or weight loss. https://www.fda.gov/drugs/drug-safety-and-availability/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss
FDA Drug Shortage: Ozempic (semaglutide) injection. https://www.fda.gov/drugs/drug-safety-and-availability/shortage-certain-individual-presentation-ozempic-semaglutide-injection-novo-nordisk
CDC Diabetes Data and Statistics. https://www.cdc.gov/diabetes/php/data-research/index.html
American Diabetes Association Standards of Care. https://www.ada.org
Soriano EC, et al. Social Media and Semaglutide. JAMA Intern Med. 2023. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2809919
Ahrén B, et al. Semaglutide and glycaemic outcomes in type 2 diabetes. Diabetes Obes Metab. 2017. https://pubmed.ncbi.nlm.nih.gov/28930514/
Nauck MA, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes. Diabetes Obes Metab. 2021. https://pubmed.ncbi.nlm.nih.gov/33567185/